Long Term Outcome on Brain and Lung of Different Oxygen Strategies in ARDS Patients
NCT03621293 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 259
Last updated 2018-08-08
Summary
Acute respiratory distress syndrome (ARDS) is a serious disease with high mortality. In patients who survive ARDS, respiratory, neurological and motor sequelae are frequent, negatively impacting on the patient's quality of life, and engendering substantial healthcare costs (rehabilitation, long-term care, delayed return to work). There may also be repercussions on the patient's family and entourage. The severity of ARDS and the burden it represents have underpinned intensive research to identify treatment strategies that could improve mortality. However, it is important to ensure that any improvement in mortality does not come at the price of an excess of sequelae and disability in survivors.
The oxygenation strategy used to treat ARDS may have an impact on mortality in these patients. The CLOSE study, in which our group participated, recently demonstrated the feasibility of two oxygenation strategies in intensive care unit (ICU) patients with ARDS. We have also initiated the LOCO-2 study (NCT02713451), whose aim is to show a reduction in mortality in ARDS using a "conservative" oxygenation strategy (PaO2 maintained between 55 and 70 mmHg) as compared to a classical "liberal" oxygenation strategy (PaO2 between 90 and 105 mmHg).
The LTO-BLOXY study is a substudy of the on-going LOCO-2 study
Conditions
- Acute Respiratory Distress Syndrome
Interventions
- DRUG
-
Modulation of Inspired Fraction of Oxygen (FiO2)
In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG). This management of FiO2 will be done until extubation of the patient.
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Besancon
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-20
- Primary Completion
- 2021-03-20
- Completion
- 2021-09-20
Countries
- France
Study Locations
More Related Trials
-
Selective Lung Recruitment in Moderate to Severe ARDS : a Pilot Study
NCT06609629 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS)
NCT00538928 ·Status: COMPLETED ·Phase: NA
-
Severe ARDS: Generating Evidence
NCT03021824 ·Status: COMPLETED
-
Artificial Intelligence in Categorizing the Severity of Oxygenation by Incorporating the PEEP Into the Definition of ARDS in Ventilated Patients
NCT05371314 ·Status: UNKNOWN
-
Comparison of Positive End Expiratory Pressure Titration Methods in ARDS Patients
NCT03281473 ·Status: UNKNOWN ·Phase: NA
-
Sigh in Acute Hypoxemic Respiratory Failure
NCT03201263 ·Status: COMPLETED ·Phase: NA
-
Prehospital High-Flow Nasal Oxygen Therapy
NCT03326830 ·Status: COMPLETED ·Phase: NA
-
Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome
NCT02818049 ·Status: TERMINATED ·Phase: NA
-
Incidence of Dyssynchronies in Early ARDS
NCT03447288 ·Status: UNKNOWN
-
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
NCT02622724 ·Status: TERMINATED ·Phase: PHASE3
-
ARDS Caused by COVID-19
NCT04368975 ·Status: UNKNOWN
-
Flow veRsus OxygeNaTion In acutE ReSpiratory Failure
NCT03223948 ·Status: UNKNOWN ·Phase: NA
-
Standardized Application of High Frequency Oscillatory Ventilation in the Acute Respiratory Distress Syndrome (ARDS)
NCT01677130 ·Status: COMPLETED
-
Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality
NCT01677117 ·Status: UNKNOWN
-
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
NCT04725084 ·Status: COMPLETED
-
Enhanced Lung Protective Ventilation With ECCO2R During ARDS
NCT03525691 ·Status: TERMINATED ·Phase: NA
-
Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome
NCT02178982 ·Status: COMPLETED
-
Lung Open Ventilation to Decrease Mortality in the Acute Respiratory Distress Syndrome
NCT00182195 ·Status: COMPLETED ·Phase: PHASE3
-
Hyperoxia Induced Pulmonary Inflammation and Organ Injury: a Human in Vivo Model
NCT05414370 ·Status: RECRUITING ·Phase: NA
-
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO
NCT03764319 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
NCT05384379 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS
NCT02282657 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of FiO2 on PaO2/FiO2 Ratio
NCT03156218 ·Status: UNKNOWN ·Phase: NA
-
Early Spontaneous Breathing in Acute Respiratory Distress Syndrome
NCT01862016 ·Status: UNKNOWN ·Phase: NA
-
Hemodynamic Effects of PEEP in ARDS
NCT03896802 ·Status: UNKNOWN ·Phase: NA